Expert views

resource-image

ACC 2024 Industry-Expert Theater
Upcoming Events

The HDL Hypothesis: Past, Present, and Future

Following an AMI, the risk of recurrent CV events remains high, particularly during the first 90 days. Despite advances in standard of care treatment, an unmet therapeutic need persists for these patients. This engaging symposium brings together an expert faculty to explore the mechanism of cholesterol efflux and its impact on post-AMI CV events. The panel will outline the pivotal role ApoA-I, a key functional component of HDL, plays in this setting, and discuss recent developments in the high-risk post-AMI landscape.

Add to Calendar 2024-04-06 18:45:00 2024-04-06 19:45:00 The HDL Hypothesis: Past, Present, and Future Following an AMI, the risk of recurrent CV events remains high, particularly during the first 90 days. Despite advances in standard of care treatment, an unmet therapeutic need persists for these patients. This engaging symposium brings together an expert faculty to explore the mechanism of cholesterol efflux and its impact on post-AMI CV events. The panel will outline the pivotal role ApoA-I, a key functional component of HDL, plays in this setting, and discuss recent developments in the high-risk post-AMI landscape. Industry-Expert Theater #3 DiscoverCholesterolEfflux CholesterolEfflux@CSLBehring.com Europe/Berlin public right
More Details
Prof Stephen Nicholls
General

Evolution of the HDL hypothesis: Current insights

Listen to Prof Stephen Nicholls provide his expert insights on why the HDL hypothesis is shifting from a focus on HDL levels to HDL function. He describes ApoA-I, the key functional component of HDL, and the role it plays in the mechanism of cholesterol efflux, the pivotal first step in reverse cholesterol transport

Listen Now
Susan Gabriel, Ph.D.
ESC22

Recurrent CV events post-AMI in patients with MVD: A retrospective study in the UK

Listen to Dr. Susan Gabriel share her insights on risk factors for recurrent cardiovascular events following myocardial infarction in a large real-world data analysis of 78,000 patients with multivessel disease.

Listen Now
Dr. C. Michael Gibson, Dr. Serge Korijan
AHA22

Residual Cardiovascular Risk Despite Secondary Prevention: Data from Contemporary Cardiovascular Outcomes Trials From 2010-2021

Listen to Dr. C. Michael Gibson and Dr. Serge Korjian discuss expert insights on the recurrent cardiovascular risk in patients with contemporary CV outcomes trials between 2010-2021.  

Listen Now
Dr Kenneth Mahaffey
General

90-day Window Unmet Need Video

Join Dr Kenneth Mahaffey, MD as he explores the impact of recurrent MI and explains why there is currently an unmet need for therapies that can reduce the risk of recurrent cardiovascular events in the high-risk 90-day period after an AMI.

Watch now
Prof. C. Michael Gibson
ACC21

Risk and incidence of recurrent CV events post-ACS: a meta-analysis - Prof. Michael Gibson

Listen to Prof. Michael Gibson discuss the risks associated with early and late recurrent events in patients with recent ACS, and the implications this could have on trial design.

Listen now
Prof. C. Michael Gibson
ACC21

Cholesterol efflux and cardiovascular outcomes - Prof. Michael Gibson

Listen to Prof Michael Gibson as he explores the association between cholesterol efflux and adverse CV events. He also discusses the potential of cholesterol efflux as a novel therapeutic target to improve outcomes for patients with CV disease.

Listen now
Dr Keith Allen
AHA20

Major adverse cardiovascular events and hospital readmissions in the 90 days following AMI: redefining the risk period

Listen to Dr. Keith Allen discuss the impact of recurrent CV events in the high-risk 90-day period post AMI.

Listen now
Dr Anand Rohatgi
General

Cholesterol efflux capacity: what is it and what does it mean for cardiovascular outcomes?

Listen to Dr Anand Rohatgi describe the process of cholesterol efflux and the data that demonstrate the importance of cholesterol efflux in determining cardiovascular outcomes.

Listen now
General

The importance of ApoA-I in cholesterol efflux and atherosclerosis

This video provides an overview of the important role apolipoprotein A1, a key functional component of high-density lipoprotein, plays in cholesterol efflux and plaque stabilization.

Watch now

Continue to

Burden of recurrent CV events

Find out about the significant healthcare costs associated with recurrent CV events post AMI1-4

See more

Current standard of care post AMI

Current standard of care and newer therapies have lowered the long-term risk of recurrent CV events; however, data show that patients are still at risk during the 90-day high-risk period after an AMI5-12

Discover more

The cholesterol story

Learn about the role of cholesterol efflux in removing excess cholesterol from lipid-laden macrophages in arterial plaque13,14

Learn more 

Get the latest news

Sign up to receive news alerts and information about educational resources to help your patients through the 90-day high-risk period post AMI

By submitting this form, you are consenting to disclose any information provided, including your name, email address, telephone number, and any other information (collectively “Personal Information”) to CSL Behring and its representatives, agents, and contractors, including CSL Behring’s support program(s) (collectively “CSL Behring Entities”) and to receive communications with relevant information from CSL Behring Entities. You may be contacted by mail, email, telephone, and/or SMS/text message in relation to our business, products, services, and educational programs intended to benefit patients using or eligible to use CSL Behring therapies. You will have the ability to opt-out from receiving communications from CSL Behring Entities at any time. CSL Behring and CSL Behring Entities will not sell your personal information. CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Abbreviations

ACC, American College of Cardiology; AHA, American Heart Association; ACS, acute coronary syndrome; AMI, acute myocardial infarction; ApoA-I, apolipoprotein A-I; ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; ESC, European Society of Cardiology; HDL, high-density lipoprotein; LDL, low-density lipoprotein

References

1. Bakhai A et al. J Interv Cardiol 2012; 25:19–27.

2. Punekar RS et al. Clin Cardiol 2015; 38:483–491.

3. Zhao Z, Winget M. BMC Health Serv Res 2011; 11:35.

4. Chapman RH et al. BMC Cardiovasc Disord 2011; 11:11.

5. Schwartz GG et al. N Engl J Med 2018; 379:2097–2107.

6. Cannon CP et al. N Engl J Med 2015; 372:2387–2397.

7. Schwartz GG et al. JAMA 2001; 285:1711–1718.

8. Bhatt DL et al. N Engl J Med 2019; 380:11–22.

9. Bhatt DL et al. J Am Coll Cardiol 2019; 73:2791–2802.

10. Mehta SR et al. N Engl J Med 2019; 381:1411–1421.

11. Wallentin L et al. N Engl J Med 2009; 361:1045–1057.

12. Nair R et al. J Am Heart Assoc 2021; 10:e019270.

13. Estrada-Luna D et al. Molecules 2018; 23:2730.

14. Silvain J et al. Curr Opin Cardiol 2019; 34:714–720.

 

USA-GEN-0051 | March 2024